Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This manuscript on real-world evidence (RWE) in pulmonary hypertension (PH) incorporates the broad experience of members of the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative Real-World Evidence Working Group. We aim to strengthen the research community's understanding of RWE in PH to facilitate clinical research advances and ultimately improve patient care. Herein, we review real-world data (RWD) sources, discuss challenges and opportunities when using RWD sources to study PH populations, and identify resources needed to support the generation of meaningful RWE for the global PH community.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10739115 | PMC |
| http://dx.doi.org/10.1002/pul2.12317 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Established and Emerging Therapies for Cardiovascular-Kidney-Metabolic Syndrome: Harnessing the Benefits of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and Beyond.
Heart Lung Circ
September 2025
Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, SA, Australia; Adelaide Medical School, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, SA, Australia; Department of Cardiology, Central Adelaide Local Health Network, Adelaide, SA,
Cardiovascular-kidney-metabolic (CKM) syndrome is a term that is increasingly used to describe interconnected conditions that lead to poor health outcomes, including cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. Historically, there have been very few targeted pharmacotherapies available that have changed cardiovascular outcomes for people with CKM syndromes; however, over the past decade, new pharmacologic options have rapidly expanded, with strong evidence for cardiovascular and kidney protective benefits in CKM conditions. Of note, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists have emerged as key therapeutic options and are now widely guideline-endorsed.
View Article and Find Full Text PDFReal-world validation of a bleeding prediction algorithm in levonorgestrel intrauterine device users using the MyIUS mobile app.
Contraception
September 2025
Bayer Aktiengesellschaft, Wuppertal - Aprath, Germany.
Objective: This study aimed to validate the real-world performance of the MyIUS mobile-application algorithm in predicting bleeding intensity and regularity in levonorgestrel intrauterine device (LNG-IUD) 52 mg, 19.5 mg, and 13.5 mg users following device insertion.
View Article and Find Full Text PDFEpidemiology, Real-World Treatment, and Economic Burden of Waldenström Macroglobulinemia: A Comprehensive Analysis Based on Anonymized Claims Data Between 2010 and 2022.
Value Health Reg Issues
September 2025
Department of Hematology and Medical Oncology, University Medical School Mainz, Mainz, Germany.
Objectives: This study aimed to provide evidence on the epidemiology, real-world treatment patterns, overall survival, and economic burden of Waldenström macroglobulinemia (WM).
Methods: A retrospective analysis of an anonymized large German claims database from January 1, 2010, to June 30, 2022, identified incident WM cases based on a 12-month diagnosis-free period before the first confirmed WM diagnosis (ICD-10-GM code C88.0).
A real-world pharmacovigilance study of FDA Adverse Event Reporting System events for gefitinib and docetaxel.
Eur J Clin Pharmacol
September 2025
Department of Pharmacy, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Background: In recent years, gefitinib and docetaxel, as targeted and chemotherapeutic agents, respectively, have been widely used in the treatment of non-small cell lung cancer (NSCLC). However, the safety of these drugs remains a significant concern in clinical practice. Comparative studies on the safety of these two drugs have yet to be fully explored.
View Article and Find Full Text PDFReal-World Adherence and Persistence of Upfront Therapy in Patients with Pulmonary Arterial Hypertension in the United States.
Pulm Ther
September 2025
Division of Pulmonary, Critical Care and Sleep Medicine, Tufts Medical Center, Boston, MA, USA.
Introduction: Pulmonary arterial hypertension (PAH) is a rare, progressive disease resulting from elevated pulmonary arterial pressure leading to right ventricular failure and death. Optimal adherence and persistence to medical therapy are necessary to improve outcomes. The objective of this study was to characterize adherence and persistence to first-line PAH therapies in patients newly initiating treatment.
View Article and Find Full Text PDF